FEATURED SEARCH TERM: Multiple sclerosis
As multiple sclerosis is a disease in which established therapies are limited, combination therapy would seem to be a promising solution by treating multiple mechanisms of the disease simultaneously. Although a recently published study failed to show any benefits from combining simvastatin(Drug information on simvastatin) and interferon-β1a, find out why combination therapy is nonetheless a promising concept and why statins are still worth considering as part of the strategy.
RESULT: Multiple sclerosis: Combination Therapy in MS—still a valid strategy
Nature Reviews Neurology | Dec 2011 (FREE FULL TEXT)
Current research is exploring how to ease brain deterioration in the primary stages of MS. The report below draws promising conclusions from five years of followup among MS patients treated with interferon for only two years. Immunomodulators are worth continued investigation, say the researchers.
RESULT: Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Followup
Archives of Neurology | Nov 1, 2011 (Free abstract. Full text $30)
